Tiziana Life Sciences Reports Six-Month Qualitative Results For All 10 Non-Active Secondary Progressive Multiple Sclerosis Patients Enrolled In Intermediate-Size Patient Population Expanded Access Program
$TLSA
Biotechnology: Pharmaceutical Preparations
Health Care
- Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.
- FDA Allowance for an additional 20 Patients to be enrolled in the intranasal foralumab Multiple Sclerosis Expanded Access Program will allow further data collection and analysis.
- Applied for FDA Orphan Drug Designation of foralumab for na-SPMS